- Home
- VRCA vs VNRX Comparison
VRCA vs VNRX Comparison
Compare VRCA & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VRCA | VNRX |
|---|---|---|
| Founded | 2013 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.5M | 31.9M |
| IPO Year | 2018 | 2012 |
Fundamental Metrics
Financial Performance| Metric | VRCA | VNRX |
|---|---|---|
| Price | $6.11 | $0.19 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $17.00 | $2.50 |
| AVG Volume (30 Days) | 125.6K | ★ 1.5M |
| Earning Date | 06-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $35,577,000.00 | $1,233,511.00 |
| Revenue This Year | $372.93 | $68.22 |
| Revenue Next Year | N/A | $382.75 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 370.22 | 59.10 |
| 52 Week Low | $0.39 | $0.17 |
| 52 Week High | $9.82 | $0.94 |
Technical Indicators
Market Signals| Indicator | VRCA | VNRX |
|---|---|---|
| Relative Strength Index (RSI) | 51.31 | 36.92 |
| Support Level | $5.22 | $0.17 |
| Resistance Level | $6.44 | $0.27 |
| Average True Range (ATR) | 0.46 | 0.02 |
| MACD | 0.16 | 0.00 |
| Stochastic Oscillator | 70.51 | 17.93 |
Price Performance
Historical ComparisonAbout VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
About VNRX VolitionRX Limited
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.